ENGNLFRA ABOUT US HISTORY PRODUCTS JOB OPPORTUNITIES NEWS DEONTOLOGY HOME HomeNewsNews Detail NEWS 01 Dec 2020 MENARINI RICERCHE ANNOUNCES SEL24/MEN1703 PHARMACODYNAMIC DATA FROM THE DOSE ESCALATION PART OF DIAMOND-01 TRIAL SEL24/MEN1703 is being Evaluated for the Treatment of Acute Myeloid Leukemia (AML) Poster Accepted for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Pomezia, Italy, December 1st, 2020 – Menarini Ricerche, the R&D division of the Menarini Group, reported today the positive results of the pharmacodynamic assay demonstrating target engagement in the dose escalation part of the DIAMOND-01 trial (CLI24-001; clinicaltrials.gov identifier NCT03008187), a study investigating SEL24/MEN1703, a first-in-class, orally available, dual PIM/FLT3 inhibitor as single agent in Acute Myeloid Leukemia (AML). The poster entitled “SEL24/MEN1703 provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamic (PD) Assay in the Dose Escalation Part of First-in-Human DIAMOND Trial” will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place virtually on December 5-8. “We are pleased with the preliminary, positive results observed with SEL24/MEN1703, a PIM/FLT3 inhibitor under investigation for the treatment of AML. As outlined in our ASH poster presentation, the dose escalation phase of the DIAMOND-01 trial showed that SEL24/MEN1703 has a manageable safety profile and results in a meaningful target engagement in peripheral blood and bone marrow blast cells from patients treated with SEL24/MEN1703,” said Andrea Pellacani, General Manager of Menarini Ricerche. “We look forward to continuing our investigation of SEL24/MEN1703 as a potential new treatment for this aggressive and hard-to-treat cancer, as part of our commitment to develop effective innovative therapies that can make a difference in the lives of cancer patients.” DIAMOND-01 is the First-in-Human, Phase I/II dose escalation and cohort expansion trial of SEL24/MEN1703, in-licensed by Menarini from Ryvu Therapeutics, in AML. The study has completed the dose escalation part showing a manageable safety profile up to the recommended dose of 125 mg/day, with initial evidence of anti-leukemic activity in a single agent setting. The objective of the pharmacodynamic assessment was to investigate the degree of target engagement achieved at different doses of SEL24/MEN1703, by measuring the phosphorylation of S6 (pS6), a downstream effector of the PIM/FLT3 signaling pathway. In addition, the correlation between pS6 levels and the anti-leukemic effect of SEL24/MEN1703 was assessed in samples collected from patients enrolled in the dose escalation part of the DIAMOND-01 trial. The quantitative assessment of pS6 at a single-cell level was performed both on peripheral blood (PB) and bone marrow (BM) blast cells samples. The results of this assay confirmed that meaningful target engagement was achieved, both in PB and BM blast cells, in patients treated with SEL24/MEN1703 at 100 mg/day (one dose level below the recommended dose) and at 125 mg/day. Moreover, preliminary data suggest that the PIM/FLT3 pathway inhibition might be associated with blast count reduction, particularly in those patients showing high phosphorylation of S6 at baseline. We will continue to measure target engagement with this assay in the cohort expansion part of the DIAMOND-01 trial, which is currently recruiting patients with relapsed or refractory AML in both the EU and the US. NEWS Jun 10 2020 Menarini Group Completes a Solid Year of Operating Performance Menarini Group announced its 2019 results. OUR VALUES 10 core values which originated our group's success. READ MORE » DIVISION DIAGNOSTICS Advanced technology. READ MORE » QUALITY FIRST Quality: starting point and endpoint criteria for our medicines. READ MORE » MENARINI IN THE WORLD The Menarini Group has companies located almost all over the world. READ MORE » Menarini Benelux N.V./S.A., De Kleetlaan 3, B-1831 Machelen About us History Products Menarini International Innovation & Research Job opportunities News Deontology Contact us Privacy Conditions of use Sitemap © 2021 The Menarini Group - All rights reserved Our website uses cookies, including third party cookies. In addition to Strictly necessary cookies that are essential to browse the website, the site features Functional cookies that ensure you make the most of your browsing experience, Performance cookies, that perform aggregate statistics on the website usage, as well as Targeting cookies that automatically tailor on-line ads on the preferences you expressed while browsing this or other websites. Should you wish to receive more information click on the Cookie Policy. To inhibit Functional cookies, Performance cookies, Targeting cookies and/or cookies of specific third parties click on MORE OPTIONS. By clicking I ACCEPT you will be accepting all the mentioned types of cookies. I ACCEPT MORE OPTIONS